期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤新生血管示踪剂RRL机制研究 被引量：4

Mechanism Study on Tumor Angiogenic Blood Vessels Tracer,RRL
原文传递
导出
摘要 [目的]研究新型血管示踪剂RRL与肿瘤来源内皮细胞结合的机制,研究血管内皮生长因子受体亚型2(VEGFR-2)是否为RRL与内皮细胞结合的靶点。[方法]设计合成纯度达到99%以上的小分子肽RRL,绿色荧光素FITC标记氨基端,培养VEGFR-2表达量不同的细胞系与RRL结合,激光共聚焦显微镜观察RRL结合不同细胞能力的差异。[结果]不同VEGFR-2受体表达量的细胞系结合RRL的能力也存在差异,差异有一致性。[结论]新型血管示踪剂RRL能够结合于高表达VEGFR-2受体的内皮细胞,VEGFR-2可能是RRL与肿瘤血管内皮细胞靶向结合的作用位点。
作者 卢霞 王荣福
机构地区 北京大学第一医院
出处 《肿瘤学杂志》 CAS 2010年第6期449-452,共4页 Journal of Chinese Oncology
基金 国家自然科学基金(30870729 30900374) 教育部教育振兴行动计划特殊专项("九八五"工程:Ⅱ期)资助项目(985-2-056) 国家重点基础研究发展计划(973计划)(2006CB705705) 高等学校博士学科点专项科研基金(20080001106)
关键词 肿瘤新生血管显像 RRL VEGFR-2受体
分类号 R730.231 [医药卫生—肿瘤]
  • 相关文献

参考文献4

  • 1张春丽,杨铭,王荣福.RGD肽与整合素α_vβ_3受体结合的构效关系及放射性标记配体的设计[J].肿瘤学杂志,2009,15(1):76-81. 被引量：19
  • 2Brown CK, Modzelewski RA, Johnson CS, et al. A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library [J]. Ann Surg Oncol, 2000, 7(10):743-749.
  • 3Weller GE, Wong MK, Modzelewski RA, et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginineleucine[J]. Cancer Res, 2005, 65(2):533-539.
  • 4Yu MM, Wang RF, Yan P, et al. Design, synthesis and iodination of an Arg-Arg-Leu peptide for potential use as an imaging agent for human prostate carcinoma [J]. J Label Compd Radiopharm, 2008, 51(11): 374-378.

二级参考文献32

  • 1黄云鹏,林建华,林志雄.整合素α_vβ_3在肿瘤血管生成中的作用[J].中国肿瘤,2007,16(1):35-38. 被引量：19
  • 2Plow EF, Haas TA, Zhang L, et al. Ligand binding to integrins[J]. J Biol Chem, 2000, 275(29): 21785-21788.
  • 3Xiong JP, Stehle T, Diefenbach B, et al. Crystal structure of the extracellular segment of integrin alpha(v)beta(3)[J]. Science, 2001, 294(5541): 339-345.
  • 4Xiong JP, Stehle T, Zhang R, et al. Crystal structure of the extracellular segment of integrin alpha(v)beta(3) complex with an Arg-Gly-Asp ligand[J]. Science, 2002, 296 (5565): 151-155.
  • 5Sutcliffe-Goulden JL, O'Doherty MJ, Marsden PK, et al. Rapid solid phase synthesis and biodistribution of ^18 F-labelled linear peptides [J]. Enr J Nucl Med Mol Imaging, 2002, 29(6):754-759.
  • 6Sivolapenko GB, Skarlos D, Pectasides D, et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide [J]. Eur J Nucl Med, 1998, 25(10):1383-1389.
  • 7Haubner R, Gratias R, Diefenbach B, et al. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αvβ3 antagonists[J]. J Am Chem Soc, 1996, 118(32):7461-7472.
  • 8Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies[J]. Curr Pharm Des, 2004, 10(13): 1439-1455.
  • 9Haubner R, Bruchertseifer F, Bock M, et al. Synthesis and biological evaluation of a ^99mTc-labelled cyclic RGD-peptide for imaging the αvβ3expression [J]. Nuklearmedizin, 2004, 43(1): 26-32.
  • 10van Hagen PM, Breeman WA, Bernard HF, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy [J]. Int J Cancer, 2000, 90(4):186-198.

共引文献18

同被引文献61

  • 1王荣福.肿瘤PET药物的现状和展望[J].核化学与放射化学,2006,28(2):65-71. 被引量：14
  • 2王荣福.核医学[M].第2版.北京:北京大学医学出版社,2009.129-149.
  • 3Weller GER, Wong MKK, Modzelewski RA. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginineleucine[J]. Cancer Research, 2005, 65(2): 533-539.
  • 4Yu MM,Wang RF, Yan P, et al. Design, synthesis and iodination of an Arg-Arg-Leu peptide for potential use as an imaging agent for human prostate carcinoma [J]. J Label Compd Radiopharm, 2008, 51(11): 374-378.
  • 5Patton JA, Townsend DW, Hutton BF. Hybrid imaging technology: from dreams and vision to clinical devices[J]. Semin Nucl Med, 2009, 39(4):247-263.
  • 6Weber WA, Grosu AL, Czernin J. Technology insight: advances in molecular imaging and an appraisal of PET/CT scanning[J]. Nat Clin Pract Oncol, 2008, 5(3):160-170.
  • 7Wehrl HF, Sauter AW, Judenhofer MS, et al. Combined PET/MR imaging-technology and applications [J]. Technol Cancer Res Treat, 2010, 9(1): 5-20.
  • 8Liu M, Wang RF, Zhang CL, et al. Noninvasive imaging of human telomerase reverse transcriptase (hTERT) messenger RNA with ^99mTc-radiolabeled antisense probes in malignant tumors[J]. J Nucl Med, 2007, 48(12): 2028-2036.
  • 9Lu X, Wang RF. A concise review of current radiopharma- ceuticals in tumor angiogenesis imaging [J]. Curr Pharm Des, 2012,18(8): 1032-1040.
  • 10Pacini F,Castagna MG,Brilli L,et al. Thyroid cancer. ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol,2010,21 (Suppl 5) :v214-v219.

引证文献4

二级引证文献19

肿瘤学杂志
2010年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部